ImmunoSite Upgrades ISO 9001:2015 and ISO 13485:2016 Dual Certification to Latest International Standards // ImmunoSite Technologies

Miramar, Fla. – October 2, 2017 – ImmunoSite Technologies, LLC, a leading global provider of contract R&D services, upgrades their dual ISO certifications from American Global Standard to the new standards as another step in their commitment to quality and customer service.

ImmunoSite Technologies Automation Services are concentrated on fulfilling the special needs of life science industries.  Turnkey custom  integrated solutions using best-of-breed liquid handlers and integrated components are developed according to the ISO standards product realization requirements, and delivered to clients only after the systems pass rigorous biological acceptance testing.  ImmunoSite scientists and engineers perform all development and testing in ImmunoSite’s state of the art laboratory facilities with the client’s particular processes and samples.

“Since the formation of ImmunoSite in 2009, product quality and client satisfaction have been the most important goals.  Our proactive decision to become certified for both ISO 9001:2015 and ISO 13485:2016  anticipates the demands of our global customers and formalizes our continuing commitment to provide additional metrics for high quality products and services,” stated Dr. Carlos Aparicio, CEO Immunosite Technologies.

Biomarkers Enhance Astra Zeneca's Clinical Trial Successes // ImmunoSite Technologies

Biomarker data from Astra Zeneca demonstrates that biomarkers enhance success in every aspect (safety, dosing, efficacy, patient selection) of every state of the drug development process.  The huge investment in a new testing paradigm to address the new types of therapeutics was worth it for AZ, and will benefit not only all companies in the pharmaceutical industry, but mankind since we can expect to see an increase in the number of efficacious therapies sooner rather than later!

Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework.  David Cook,Dearg Brown, Robert Alexander, Ruth March, Paul Morgan, Gemma Satterthwaite & Menelas N. Pangalos.  Nature Reviews Drug Discovery (2014).  DOI: doi:10.1038/nrd4309. Published online 16 May 2014

ImmunoSite Receives 2013 Innovative Business Award // ImmunoSite Technologies

ImmunoSite Technologies, LLC was receives the 2013 Innovative Business award from BB&T in December, for their innovative services and custom products provided to Pharmaceutical and other Life Science industries globally.  Congratulations to all of the winners: WorkForce One, Downtown Development Authority, Hilton Fort Lauderdale Beach Resort, ProdecoTech, United Way of Broward County, Broward Health Medical Center, Community Foundation of Broward County, Broward College, FP&L, Resolve Marine Group, ImmunoSite Technologies and SmartWater CSI.

ImmunoSite Receives National MBE Certification // ImmunoSite Technologies

02/01/2014. ImmunoSite Technologies was certified as a National MBE, Minority Business Enterprise, by the Southern Florida Minority Supplier Development Council as defined by the U.S. National Minority Supplier Development Council.  The NMSDC was chartered in 1972 and is one of the country’s leading corporate membership organizations to advance business opportunities for certified business enterprises of all sizes, by connecting MBEs with corporate members interested in maintaining supplier diversity in their businesses. There are over 3,500 corporate members, including most of America’s largest public, private and foreign-owned companies, as well as universities, hospitals and other buying institutions.

ImmunoSite Technologies Expands into New Spacious Facility in Miramar // ImmunoSite Technologies

Press Release, February 28, 2013

ImmunoSite Technologies, LLC (IST), a provider of automation, design and customization of complex biological assays to biotechnology and pharmaceutical industries worldwide, announced its relocation to a newly expanded facility at 2831 Corporate Way in Miramar.  With the expansion, the company will be retaining its current employees, making a capital investment of $150,000 and adding 5 new jobs that will focus on product development.

READ MORE

2013 SLAS 2nd Annual Conference & Exhibition // ImmunoSite Technologies

Executives, Engineers, and Scientists from ImmunoSite Technologies attended the Annual 2013 SLAS meeting in Orlando, Florida and brought back some of the latest technologies to integrate into new automated solutions for biological assay automation that will enhance their client’s productivity even more!

Call IST to discuss your automation needs at (888) 770-4478

ImmunoSite Technologies Aides in Curriculum Development for Employ Florida Banner Center // ImmunoSite Technologies

Cell Culture Course helps Floridians enter, remain and advance in the workforce

Fort Lauderdale, Fla. – October 18, 2011 – ImmunoSite Technologies (IST), LLC, a leading provider of immune monitoring services, has helped to develop a Cell Culture Workshop that is offered  at the Employ Florida Banner Center for Life Sciences, based at Palm Beach State College’s Eissey Campus in Palm Beach Gardens.

READ MORE

ImmunoSite Technologies Provides Particle Testing Services to Beckman Coulter Customers // Admin

Leading provider of particle testing services now receives referrals of customers seeking particle characterization services from Beckman Coulter, Inc.

Fort Lauderdale, Fla. – April 3, 2011 – ImmunoSite Technologies, LLC, a leading provider of immune monitoring services, is now receiving direct customer referrals for particle testing services from Beckman Coulter, Inc. as part of a recent collaboration agreement.

READ MORE